» Articles » PMID: 29682296

Intensification of Antiretroviral Treatment with Raltegravir for Pregnant Women Living with HIV at High Risk of Vertical Transmission

Overview
Journal J Virus Erad
Date 2018 Apr 24
PMID 29682296
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

 The rate of vertical HIV transmission for women at high risk of HIV transmission stands at approximately 7.6%. In the present study we describe infant infection rates in women who had received raltegravir (RAL) intensification during pregnancy to a standard three-drug antiretroviral (ART) regimen in Thailand.  This prospective cohort study enrolled HIV-1-positive pregnant women at high risk of vertical transmission, as defined by (1) ART initiation at a gestational age (GA) ≥32 weeks or (2) HIV-1 RNA >1000 copies/mL at GA of 32-38 weeks while on ART. Women received a standard three-drug ART regimen with RAL intensification (400 mg twice daily) until delivery and continued on a three-drug ART regimen after delivery. Plasma HIV-1 RNA testing was performed before intensification and at delivery. Infant HIV-1 status was determined using DNA PCR at birth, and at 1, 2 and 4 months of life.  Between February 2016 and November 2017, 154 pregnant women on ART were enrolled into the study with a median CD4 cell count and plasma HIV-1 RNA level of 382 cells/mm and 4.0 log copies/mL, respectively. The three-drug combination consisted of either a lopinavir/ritonavir- (53%) or efavirenz-based (43%) regimen. Median GA at time of RAL initiation was 34 weeks (interquartile range [IQR] 33-36) and median duration was 21 days (IQR 8-34). The proportion of women who had a plasma HIV-1 RNA <50 and <1000 copies/mL at delivery was 45% and 76%, respectively. There were six infants with HIV infection, three in utero and three peripartum. Overall vertical transmission rate was 3.9% (95% confidence interval [CI] 1.4-8.2).  The majority of high-risk pregnant women living with HIV-1 who had received RAL intensification achieved viral suppression at delivery with a relatively low rate of vertical transmission. This intensification strategy represents an option for prevention in HIV-positive women at high risk of vertical transmission.

Citing Articles

Viral load testing among pregnant women living with HIV in Mutare district of Manicaland province, Zimbabwe.

Musanhu C, Takarinda K, Shea J, Chitsike I, Eley B AIDS Res Ther. 2022; 19(1):52.

PMID: 36384677 PMC: 9667426. DOI: 10.1186/s12981-022-00480-1.


HIV in pregnancy - An update.

Chilaka V, Konje J Eur J Obstet Gynecol Reprod Biol. 2020; 256:484-491.

PMID: 33246666 PMC: 7659513. DOI: 10.1016/j.ejogrb.2020.11.034.


Husband's willingness-to-pay for HIV and syphilis screening at antenatal care clinic under the Thai universal coverage scheme.

Anunsittichai O, Pongpirul K, Puthanakit T, Roowicha K, Kaewprasert J, Songtaweesin W BMC Public Health. 2020; 20(1):480.

PMID: 32276624 PMC: 7149847. DOI: 10.1186/s12889-020-08613-9.


"Real life" use of raltegravir during pregnancy in France: The Coferal-IMEA048 cohort study.

Gantner P, Sylla B, Morand-Joubert L, Frange P, Lacombe K, Khuong M PLoS One. 2019; 14(4):e0216010.

PMID: 31017957 PMC: 6481866. DOI: 10.1371/journal.pone.0216010.

References
1.
Townsend C, Byrne L, Cortina-Borja M, Thorne C, de Ruiter A, Lyall H . Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011. AIDS. 2014; 28(7):1049-57. DOI: 10.1097/QAD.0000000000000212. View

2.
Maliakkal A, Walmsley S, Tseng A . Critical Review: Review of the Efficacy, Safety, and Pharmacokinetics of Raltegravir in Pregnancy. J Acquir Immune Defic Syndr. 2016; 72(2):153-61. DOI: 10.1097/QAI.0000000000000932. View

3.
Lennox J, DeJesus E, Lazzarin A, Pollard R, Madruga J, Berger D . Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009; 374(9692):796-806. DOI: 10.1016/S0140-6736(09)60918-1. View

4.
Lolekha R, Chokephaibulkit K, Phanuphak N, Chaithongwongwatthana S, Kiertiburanakul S, Chetchotisakd P . Thai national guidelines for the prevention of mother-to-child transmission of human immunodeficiency virus 2017. Asian Biomed (Res Rev News). 2018; 11(2):145-159. PMC: 5978732. DOI: 10.5372/1905-7415.1102.547. View

5.
Hegazi A, Mc Keown D, Doerholt K, Donaghy S, Sadiq S, Hay P . Raltegravir in the prevention of mother-to-child transmission of HIV-1: effective transplacental transfer and delayed plasma clearance observed in preterm neonates. AIDS. 2012; 26(18):2421-3. DOI: 10.1097/QAD.0b013e32835a9aeb. View